Tema Oncology ETF CANC
Source: Yahoo Finance (opens in a new tab) Observed · 1 day ago Quotes may be delayed
- Net expense ratio
- 0.75%
- Net assets
- $176.1M
- Holdings
- 57
- 12-month distribution yield
- 0.05%
- Asset class
- Equity
Tema Oncology ETF (CANC) is an exchange-traded fund listed on the Nasdaq in the United States, issued by Tema. Its category is Equity · Global (equity). Its last price was US$41.51 on 20 Oct 2026. Its net expense ratio is 0.75% a year, from its prospectus dated 29 Jun 2026. It reported net assets of US$176.14 million as of 31 May 2026. Its latest holdings report lists 57 holdings as of 31 May 2026. Over the last 12 months it paid distributions of US$0.0200 a unit, a 12-month distribution yield of 0.05%, paid yearly.
Fees
- Total annual operating expenses (gross)
- 0.99%
- Net, after fee waivers or reimbursements
- 0.75%
- Management fee
- 0.99%
- Prospectus date
- 29 Jun 2026
- Filed with the SEC
- 29 Jun 2026
Size and reporting
- Net assets
- $176,140,765
- Total assets
- $176,431,269
- Holdings as of
- 31 May 2026
- Report made public
- 29 Jul 2026 (59 days after the month end)
Top holdings
Largest 25 of 57 positions, as of 31 May 2026. Weight is the percent of net assets the fund reported.
| # | Holding | Identifier | Weight | Value (USD) | Type | Country | Currency |
|---|---|---|---|---|---|---|---|
| 1 | Revolution Medicines Inc | US76155X1000 | 7.73% | $13.6M | Equity (common) | United States | USD |
| 2 | Eli Lilly & Co | US5324571083 | 4.82% | $8.5M | Equity (common) | United States | USD |
| 3 | Roche Holding AG | US7711951043 | 4.21% | $7.4M | Equity (common) | Switzerland | USD |
| 4 | Cogent Biosciences Inc | US19240Q2012 | 4.10% | $7.2M | Equity (common) | United States | USD |
| 5 | Novartis AG | CH0012005267 | 4.03% | $7.1M | Equity (common) | Switzerland | CHF |
| 6 | Immunome Inc | US45257U1088 | 3.91% | $6.9M | Equity (common) | United States | USD |
| 7 | Celcuity Inc | US15102K1007 | 3.58% | $6.3M | Equity (common) | United States | USD |
| 8 | Merck & Co Inc | US58933Y1055 | 3.57% | $6.3M | Equity (common) | United States | USD |
| 9 | AstraZeneca PLC | GB0009895292 | 3.54% | $6.2M | Equity (common) | United Kingdom | GBP |
| 10 | Nuvalent Inc | US6707031075 | 3.37% | $5.9M | Equity (common) | United States | USD |
| 11 | Bristol-Myers Squibb Co | US1101221083 | 3.30% | $5.8M | Equity (common) | United States | USD |
| 12 | Legend Biotech Corp | US52490G1022 | 2.99% | $5.3M | Equity (common) | United States | USD |
| 13 | AbbVie Inc | US00287Y1091 | 2.81% | $4.9M | Equity (common) | United States | USD |
| 14 | Exelixis Inc | US30161Q1040 | 2.78% | $4.9M | Equity (common) | United States | USD |
| 15 | Bridgebio Pharma Inc | US10806X1028 | 2.75% | $4.8M | Equity (common) | United States | USD |
| 16 | Johnson & Johnson | US4781601046 | 2.55% | $4.5M | Equity (common) | United States | USD |
| 17 | CG oncology Inc | US1569441009 | 2.43% | $4.3M | Equity (common) | United States | USD |
| 18 | Genmab A/S | US3723032062 | 2.37% | $4.2M | Equity (common) | Denmark | USD |
| 19 | Ideaya Biosciences Inc | US45166A1025 | 2.27% | $4.0M | Equity (common) | United States | USD |
| 20 | Amgen Inc | US0311621009 | 2.11% | $3.7M | Equity (common) | United States | USD |
| 21 | Zai Lab Ltd | US98887Q1040 | 1.98% | $3.5M | Equity (common) | China | USD |
| 22 | BeOne Medicines Ltd | US07725L1026 | 1.88% | $3.3M | Equity (common) | United States | USD |
| 23 | Zymeworks Inc | US98985Y1082 | 1.51% | $2.7M | Equity (common) | United States | USD |
| 24 | Enliven Therapeutics Inc | US29337E1029 | 1.31% | $2.3M | Equity (common) | United States | USD |
| 25 | Relay Therapeutics Inc | US75943R1023 | 1.28% | $2.3M | Equity (common) | United States | USD |
Breakdowns
Sums of reported weights over every position in the report. Totals can differ from 100% because of derivatives, borrowing and cash.
Asset type
| Type | Weight | Bar |
|---|---|---|
| Equity (common) | 98.99% | |
| Short-term investment vehicles (cash funds) | 1.09% |
Country
| Country | Weight | Bar |
|---|---|---|
| United States | 80.91% | |
| Switzerland | 8.24% | |
| United Kingdom | 4.04% | |
| Denmark | 2.37% | |
| China | 1.98% | |
| Germany | 1.12% | |
| Japan | 0.67% | |
| Hong Kong | 0.44% | |
| Cayman Islands | 0.30% |
Currency exposure
| Currency | Weight | Bar |
|---|---|---|
| US dollar (USD) | 91.85% | |
| Swiss franc (CHF) | 4.03% | |
| British pound (GBP) | 3.54% | |
| Japanese yen (JPY) | 0.67% |
Sector
| Sector | Weight | Bar |
|---|---|---|
| Health Care | 47.73% | |
| Health Technology | 3.37% |
Source: SEC Form N-PORT (opens in a new tab) Holdings as of
Distributions
- Paid in the last 12 months
- $0.0200
- 12-month yield
- 0.05%
- Frequency
- Yearly
- Latest ex-date
- 10 Dec 2025
12-month yield = distributions per unit with an ex-date in the last 12 months ($0.0200) ÷ latest price ($41.51) × 100 = 0.05%. It looks back, so it is not a forecast; special distributions in the window are included.
Why a distribution yield is not the fund's return: yield vs total return
Distribution history table (3 payments)
| Ex-date | Amount per unit |
|---|---|
| 10 Dec 2025 | $0.0200 |
| 11 Dec 2024 | $0.7280 |
| 13 Dec 2023 | $0.1490 |
Filings and sources
- Form N-PORT report for May 2026 (opens in a new tab)
- Prospectus filing with the fee table (opens in a new tab)
- All SEC filings for this fund series (S000078299) (opens in a new tab)
- Nasdaq Trader symbol directory (opens in a new tab)
- Yahoo Finance quote and distributions (opens in a new tab)
- How the ETF figures are collected
Compare with
Largest funds in the same category:
- CANC and VT Vanguard Total World Stock Index ETF
- CANC and SMH VanEck Semiconductor ETF
- CANC and SOXX iShares PHLX SOX Semiconductor Sector Index Fund
- CANC and CGDV Capital Group Dividend Value ETF